Colombia IVD Registration Under Decreto 3770 de 2004

1. Key takeaways

In vitro diagnostic reagents (reactivos de diagnóstico in vitro) in Colombia do not follow Decreto 4725 de 2005; they are legislated separately under Decreto 3770 de 2004. Article 1 of Decreto 4725 de 2005 expressly excludes in vitro diagnostic reagents from its scope of application. IVDs carry their own three-tier classification: Categoría I, II and III. This scheme cannot be mapped onto the device classification of I/IIa/IIb/III — calling a Categoría II reagent a Class II device is a conceptual mismatch that leads directly to pathway errors.

The intensity difference between the tiers shows up in validity periods and entry mode: Categoría I/II certificates are valid for 10 years and Categoría III for 5 years; on a practical estimate, Categories I/II proceed mainly by registration listing while Category III requires prior approval (the specific processing approach follows INVIMA’s current publications). On the 2026 fee schedule, IVD Class I/II registration costs COP 2,570,590 and IVD Class III costs COP 3,427,327. GRZAN’s judgment: the risk in IVD projects lies not in the fee level but in the habitual use of the device framework to understand reagent regulation — the two systems were separated at the legislative source.

2. Legal basis

3. Expert insights

#### Separate legislation means no cross-system analogy

Devices run on Decreto 4725 de 2005 and reagents on Decreto 3770 de 2004; the two decrees are not aligned in legislative timing, classification logic or validity rules. Devices carry a uniform 10-year validity, while IVD Categoría III has only 5 years; devices are classified in four tiers, reagents in three. GRZAN holds one discipline in client communication: every internal document on an IVD project must state Categoría X under Decreto 3770 de 2004 and never a bare Class II. This drafting distinction blocks most downstream pathway confusion.

#### The validity gap is a direct projection of risk tiering

Categoría I/II validity of 10 years versus Categoría III validity of 5 years is not a technical setting but the authority’s judgment on risk persistence: clinical and performance evidence for high-risk reagents must return to regulatory view more frequently. For holders of Categoría III certificates, this effectively doubles the compliance review frequency. GRZAN manages this on a project basis: renewal actions for Categoría III start within 6 months before expiry — a wider window than the devices’ 3 months, precisely to leave room for the heavier dossier preparation.

#### Semantic standards and UDI apply to IVDs in parallel, and every transition has lapsed

The semantic standards and UDI-DI requirements of Resolución 1405 de 2022 apply simultaneously to medical devices and IVD reagents. Transitions were tiered by risk: 12 months for IVD Category III (ending February 8, 2025), 18 months for Category II (ending August 8, 2025), and 24 months for Category I (ending February 8, 2026); registrations obtained on or after February 8, 2024 must complete them before commercialization; and an official INVIMA communication of March 12, 2026 confirmed that semantic reporting is now fully mandatory. IVD companies therefore have no buffer left — all three transition periods expired before the verification date.

#### The new decree would merge the two systems into one framework

The draft Proyecto de Decreto on the Régimen Sanitario de Dispositivos Médicos aims to update Decreto 4725/2005 and Decreto 3770/2004 as a whole, bringing IVDs and SaMD into a unified framework. The draft was published in January 2026, went through WTO international notification on May 18, 2026, closed its comment period on July 17, 2026, and itself proposes an 18-month transition period; as of the verification date it has not been signed or promulgated. GRZAN’s judgment: convergence is the certain direction, but whether IVD tiers will align with device tiers after convergence requires article-by-article comparison of the published text; until then, all IVD work proceeds under Decreto 3770 de 2004.

4. Practical recommendations

1. At project initiation, the GRZAN regulatory team issues an IVD tier determination memo stating Categoría I/II/III explicitly and noting that the basis is Decreto 3770 de 2004, not the device classification rules.
2. The registration team builds a validity ledger by tier: 10 years for Categoría I/II and 5 years for Categoría III; renewal for Categoría III starts within 6 months before expiry.
3. Finance budgets on the 2026 fee schedule: IVD Class I/II at COP 2,570,590 and IVD Class III at COP 3,427,327, reserving a legal-nature modification fee of COP 826,546 and a technical-nature modification fee of COP 1,060,243.
4. Compliance verifies the UDI-DI and GMDN semantic reporting required under Resolución 1405 de 2022 and confirms the issuing agency is within the GS1, HIBCC, ICCBBA, IFA, Ali Health or ZIIOT list.
5. The titular designates a Colombian legal representative (apoderado / representante legal) with the power of attorney executed per Art. 29, and all submitted documents are in Spanish or in English with official Spanish translation.
6. The strategy function tracks the signature milestone of the new draft decree and assesses transition arrangements for existing certificates after IVD and device systems converge.

5. Verification checklist

• □ It is confirmed the product is an in vitro diagnostic reagent governed by Decreto 3770 de 2004, not Decreto 4725 de 2005
• □ A Categoría I/II/III tier determination memo has been issued, with internal documents using the Categoría wording consistently
• □ The validity ledger is built separately: 10 years for I/II and 5 years for III
• □ Renewal for Categoría III is locked to start within 6 months before expiry
• □ IVD official fees and modification fees under the 2026 fee schedule are budgeted and approved
• □ UDI-DI and GMDN semantic reporting is complete, with the issuing agency on the recognized list
• □ The power of attorney (Art. 29) is valid and the local apoderado is configured as the filer

Regulatory information verified as of October 29, 2026

All external conclusions rest on the current regulatory texts published by the competent authority, verified provision by provision before delivery.

GRZAN advises IVD manufacturers on the Colombian market with Decreto 3770 de 2004 classification strategy, INVIMA registration planning and UDI compliance support. For inquiries, contact info@grzanglobal.com.